AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

AGENUS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$6.18+0.14 (+2.32%)

Close on Oct 19, 2026

Market cap: $255.47M
P/E (TTM): –
Dividend yield: –

AGENUS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	114	103	156	98	296	88	150	37	43	23	25	6.98	3.05	16	2.76	3.36	3.33
Cost of Revenue	1.02	0.49	3.11	11	3.47	2.35	–	–	–	–	–	0	0.54	0.67	0	0.12	0
Gross Profit	113	103	153	87	292	86	–	–	–	–	–	6.98	2.51	15	2.76	3.24	3.33
Research & Development	79	156	235	187	179	143	168	125	116	95	70	22	13	11	11	13	17
General & Administrative	54	72	79	81	76	59	46	37	34	33	28	21	14	11	11	12	14
Operating Income	-20	-120	-160	-179	26	-117	-70	-124	-104	-107	-81	-43	-25	-6.74	-19	-22	-28
Interest Expense	56	120	104	64	–	–	–	–	31	19	4.34	1.26	2.42	4.69	4.21	4.87	5.34
Interest & Investment Income	0.35	2.80	5.93	2.26	–	–	–	–	–	–	–	–	0.01	0.02	0.02	0.04	–
Income from Equity Investments	-26	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-2.22	5.83	0.04	13	5.05	-1.86	0.03	-2.18	1.98	-2.20	-5.97	2.10	-2.67	0.11	0.00	4.68	2.57
Asset Impairment Charges	0.23	1.97	0	6.11	0	0	0	0	0	0	0	–	–	0	0	0.63	–
Gain (Loss) on Sale of Assets	-0.94	-1.15	1.41	16	3.30	-0.20	-0.06	-0.15	-0.02	-0.01	–	0.00	-0.06	-0.01	-0.04	-0.16	-0.05
Pretax Income	-3.08	-232	-257	–	–	–	–	–	-121	-127	-93	-42	-30	–	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	-5.39	0	0	0	0	–	–
Net Income incl. Noncontrolling Interests	-3.08	-232	-257	-231	-29	-183	-112	-162	-121	-127	–	–	–	–	–	–	–
Minority Interest in Earnings	-3.20	-5.06	-12	-11	-4.80	-1.98	-3.90	-2.35	–	–	–	–	–	–	–	–	–
Net Income	–	–	–	–	–	–	–	–	-121	-127	-88	-42	-30	-11	-23	-22	-30
Preferred Dividends	0.22	0.22	0.21	0.21	0.21	0.21	0.21	0.21	0.21	0.20	0.20	0.20	3.16	0.79	0.79	0.79	0.79
Net Income to Common	-0.10	-227	-246	-220	-24	-181	-108	-160	-121	-127	-88	-43	-33	-12	-24	-23	-31
EPS (Basic)(per share)	0.00	-10.59	-13.75	-15.64	-0.11	-1.05	-0.80	-1.44	-1.23	-1.46	-1.13	-0.71	-1.12	-0.51	-1.21	-1.41	-2.36
EPS (Diluted)(per share)	0.00	-10.59	-13.75	-15.64	-0.11	-1.05	-0.80	-1.44	-1.23	-1.46	-1.13	-0.71	-1.12	-0.51	-1.21	-1.41	-2.36
Shares Outstanding (Basic, Weighted)(shares)	30	21	18	14	0.23	0.17	0.13	0.11	0.10	87	78	60	30	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	30	21	18	14	0.23	0.17	0.13	0.11	0.10	87	78	60	30	–	–	–	–
EBITDA	-10	-107	-146	-172	33	-110	-63	-118	-98	-103	-79	-42	-24	-5.12	-17	-18	-24
Provision for Credit Losses	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 99.5%
Operating margin: 27.3%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 0.34
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 8.1%

Valuation

P/E ratio: –
Price to sales: 1.93
Price to book: –
Dividend yield: –